Meet Dr. Sharon May
Meet Dr. Sharon May: The Trusted Guide Behind Stage4Hope Retreats
When you’re facing a Stage 4 cancer diagnosis, who leads you matters.
Not just their kindness — but their depth, training, experience, and ability to hold space when emotions are raw and life feels uncertain. At Stage4Hope, our retreats are led by Dr. Sharon May, a therapist, educator, and nationally respected voice in emotional healing and relational care.
Dr. May doesn’t simply facilitate conversations. She brings decades of clinical expertise and human wisdom into a space designed for people navigating one of the hardest moments of their lives.
A Foundation of Clinical Excellence
Dr. May holds a Ph.D. in Marriage and Family Therapy and a Master’s degree in Theology from Fuller Graduate School of Theology, grounding her work in both evidence-based psychology and deep understanding of meaning, identity, and emotional resilience.
She is a licensed therapist and a Certified Emotionally Focused Therapy (EFT) Therapist and Supervisor, trained in one of the most research-validated therapeutic models for emotional regulation, attachment, and secure connection. EFT is widely recognized for helping people manage fear, grief, and relational disruption — all central experiences for those facing advanced cancer.
Her academic research and doctoral work focused on attachment theory and emotional bonding, exploring how people find safety, steadiness, and connection during times of crisis. This research-informed foundation shapes every retreat she leads.
Leadership, Teaching, and National Influence
Dr. May is the Founder and President of Safe Haven Relationship Center, where she has spent years developing therapeutic curriculum, training clinicians, and guiding individuals and families through trauma, loss, and major life transitions.
She also serves on the Executive Board of the American Association of Christian Counselors (AACC), reflecting her standing as a trusted leader within the counseling profession.
In addition to her clinical practice, Dr. May is an adjunct professor who has taught counseling and therapy courses, helping shape the next generation of clinicians. She is also a frequent national speaker, presenting workshops and trainings across the U.S. and internationally.
Many people may recognize her from radio and television appearances, including Focus on the Family, Family Talk, Life Today, and her own program Arguing with Dr. Sharon. She is also the author of two books on emotional connection and communication, extending her reach well beyond the therapy room.
Why This Matters for Stage4Hope Retreats
Credentials matter — but how they translate into care matters more.
Dr. May brings all of this experience into Stage4Hope retreats with a grounded, human approach. She creates spaces that feel safe, steady, and deeply respectful. Participants are never pressured to share. Silence is welcome. Listening is participation.
In retreats like Still Me, Dr. May guides participants through:
- Grounding practices that calm racing thoughts and emotional overwhelm
- Reflection and journaling that help process shock and fear
- Gentle guidance on communicating with loved ones and setting boundaries
- Group connection rooted in dignity, confidentiality, and understanding
- Identity-centered reflection that honors the person beyond the diagnosis
This is not surface-level support. It is carefully facilitated emotional care led by someone who understands both the science of healing and the humanity of suffering.
A Guide You Can Trust
People come to Stage4Hope retreats for support — and they stay because they feel seen.
Dr. Sharon May brings credibility, calm, and compassion into every retreat she leads. Her presence reassures participants that they are in capable hands — guided by someone who understands trauma, connection, fear, hope, and the complexity of being human in the face of cancer.
That trust is everything.
If you are seeking a retreat led by a therapist with true depth, experience, and heart, you will find it here.
How 2025 Changed Cancer Care
Real Progress for Advanced Cancer Patients
For people living with advanced or hard-to-treat cancer, progress is not just about science — it’s about more time, fewer side effects, and better quality of life. In 2025, doctors and researchers reported major treatment advances that are already changing how cancer is treated today. These developments are especially meaningful for patients with stage 4 cancer who may feel they are running out of options.
Many of these breakthroughs were led or supported by research teams at Memorial Sloan Kettering Cancer Center, and they reflect a growing shift toward personalized, less invasive, and more effective cancer care.
Below is what patients need to know — without the medical jargon.
Immunotherapy Alone Is Treating Some Cancers Successfully
One of the most hopeful advances of 2025 involves cancers with a genetic feature called mismatch repair deficiency (MMRd). This feature makes cancer cells easier for the immune system to recognize and destroy.
In a large clinical trial, nearly 80% of patients with MMRd cancers — including colorectal, stomach, esophageal, bladder, and other cancers — were successfully treated using immunotherapy alone. Many patients did not need surgery, chemotherapy, or radiation.
For patients, this matters deeply. Avoiding major surgery or harsh treatments can preserve organs, reduce long-term side effects, and protect quality of life. For people with advanced cancer, it also shows that less treatment can sometimes be more effective.
New Targeted Therapies Bring Hope for Lung Cancer
For people with non-small cell lung cancer, treatment options can become limited once chemotherapy or immunotherapy stop working. In 2025, researchers reported promising results from a new targeted therapy aimed at a mutation called KRAS-G12D — a mutation that until recently had no effective treatment.
In an early clinical trial, more than 60% of patients saw their tumors shrink, even though many had already tried multiple treatments without success. This is especially important for patients searching for new targeted therapy for lung cancer after being told there are no remaining options.
This breakthrough reinforces the importance of genetic testing, even later in the disease, because new drugs continue to emerge for specific cancer mutations.
Breast Cancer Patients Are Living Longer With New Combinations
Patients with advanced breast cancer also saw meaningful progress in 2025. A large clinical trial found that combining a new targeted therapy with standard hormone treatments helped patients live about 26% longer than with standard treatment alone.
This matters because many people with metastatic breast cancer stay on treatment for years. Extending survival while maintaining daily function and independence is a major win — and another reminder that treatment plans can evolve over time.
Blood Tests Help Prevent Cancer From Returning
Another important advance involves simple blood tests, often called liquid biopsies, that can detect tiny traces of cancer left behind after surgery.
In a small study, doctors used these blood tests to identify patients who were most likely to benefit from immunotherapy after surgery. Patients who received immunotherapy based on their blood test results had strong survival rates and lower chances of recurrence.
For patients living with the fear of cancer coming back, this approach represents a more personalized and proactive strategy — treating only when needed, and earlier than before.
Progress for Rare and Overlooked Cancers
Not all breakthroughs focus on common cancers. In 2025, several advances targeted rare and aggressive diseases that historically have had few options:
-
CAR T-cell therapy showed dramatic results for patients with AL amyloidosis who had stopped responding to standard treatments
-
A new targeted drug helped shrink tumors in patients with histiocytosis, a rare blood cancer affecting both adults and children
-
Children with an aggressive brain cancer lived far longer than expected using a new drug delivery method
For families facing rare diagnoses, these advances send a powerful message: research is not standing still.
Why This Matters for Stage 4 Patients
If you are living with stage 4 cancer, the message from 2025 is clear:
New options continue to emerge — even after standard treatments fail.
Across many cancer types, these advances mean:
-
More targeted therapies with fewer side effects
-
Immunotherapy replacing or delaying invasive treatments
-
Blood tests guiding smarter decisions
-
Clinical trials offering real benefit, not just future promise
At Stage4Hope, we encourage patients and caregivers to ask about genetic testing, clinical trials, and new treatment strategies, especially when options feel limited. Knowledge can open doors — and hope often begins with asking one more question. (Source: Memorial Sloan Kettering)
Read the complete article here >
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re exploring the latest cancer treatment advances like immunotherapy or targeted therapy, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Join our community to access trusted resources, education, and encouragement from others who understand the stage 4 journey.
BLOCK-ID cancer research
BLOCK-ID: New Technique Finds Treatment Targets in Hard-to-Treat Cancers
When cancer is difficult to control, it’s often because the cancer cells have learned how to survive under intense stress. Even when their DNA is damaged or unstable — a situation that would normally cause a healthy cell to stop dividing or die — these cancer cells find ways to keep going.
This ability to survive under pressure is one reason some cancers become aggressive, resistant to treatment, or quick to return after therapy. Understanding how cancer cells manage this stress is a major focus of modern cancer research.
Researchers at Winship Cancer Institute of Emory University have now developed a powerful new research tool that helps explain how certain cancers adapt and survive under these extreme conditions. While this discovery is not a treatment yet, it offers important clues that may eventually lead to new targeted therapies for cancers that currently have limited options.
Why DNA copying matters in cancer
Every time a cell divides, it must make an exact copy of its DNA. In healthy cells, this process is carefully regulated to prevent mistakes. But in cancer cells, DNA copying often becomes chaotic.
DNA is copied at structures called replication forks, which are Y-shaped points where the DNA strands separate so new copies can be made. In many cancers, these replication forks frequently slow down, stall, or collapse. When this happens repeatedly, it creates DNA replication stress.
Replication stress is a double-edged sword. On one hand, it causes DNA damage and genetic instability — changes that can drive cancer growth and spread. On the other hand, cancer cells that learn how to survive replication stress gain a powerful advantage, allowing them to adapt, resist treatments, and continue dividing despite severe internal damage.
Many aggressive cancers exist in a constant state of replication stress. Understanding how they tolerate this stress — and which proteins help them survive it — is critical for finding new ways to disrupt cancer growth.
What is BLOCK-ID?
To better understand what happens when DNA is under stress or damage, researchers developed a new laboratory technique called BLOCK-ID, an Emory technique (short for biotinylation of lac operator array replication stress protein network identification).
In simpler terms, BLOCK-ID allows scientists to:
- Create stress in a cancer cell’s DNA on purpose.
- They then watch how cancer cells respond to that stress.
- This helps researchers see which proteins cancer cells use to survive.
This Emory technique solves a long-standing challenge in cancer research. Until now, it has been extremely difficult to identify which proteins are involved at replication forks during stress. BLOCK-ID provides a detailed and precise way to map the protein networks cancer cells rely on to survive.
A key discovery: TRIM24 and other proteins
Using BLOCK-ID, researchers identified multiple proteins that appear at stressed replication forks. One protein, called TRIM24, stood out as particularly important.
The team then applied this discovery to a specific cancer survival mechanism known as Alternative Lengthening of Telomeres (ALT).
Telomeres are protective caps at the ends of chromosomes. In normal cells, telomeres shorten each time a cell divides, which eventually limits how long a cell can continue reproducing. Cancer cells must overcome this limit to survive.
Some cancers — estimated at 10–15% — use the ALT pathway to maintain their telomeres without relying on the more common enzyme-based method. ALT is often seen in aggressive or difficult-to-treat cancers, including:
- Osteosarcoma
- Glioblastoma
- Pancreatic neuroendocrine tumors
The research showed that TRIM24 helps cancer cells protect their chromosome ends so they can keep dividing.
Why this is hopeful: four potential treatment targets
In addition to TRIM24, the researchers identified three other proteins involved in the ALT pathway. Together, these findings highlight four potential treatment targets in ALT-driven cancers.
Identifying targets is one of the most important early steps in cancer drug development. While it can take time to move from discovery to therapy, knowing which proteins are essential to cancer survival gives researchers a clearer path forward.
The next phase of research will focus on determining whether these targets can be safely disrupted — and whether doing so can slow or stop cancer growth.
What this could mean for patients
BLOCK-ID is not a new treatment, but it represents meaningful progress in understanding cancer biology. Research like this helps explain why some cancers behave aggressively and why they may stop responding to standard treatments.
For patients living with advanced or hard-to-treat cancers, this work supports a growing shift toward precision oncology — matching treatment strategies to the specific biological features of a tumor. Discoveries like this strengthen the importance of:
- Testing the cancer to learn what makes it grow
- Understanding how the cancer survives
- Looking into clinical trials when needed
As researchers uncover new weaknesses in cancer cells, new treatment options may become possible, even for patients who have been told there are few options left.
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, looking for emotional support, or trying to keep up with promising research, Stage 4 Hope is here for you. Join our community to stay connected to trusted resources, new updates, online training, and encouragement from others who understand this journey.
References:
https://winshipcancer.emory.edu/newsroom/articles/2025/new-technique-identifies-potential-new-treatment-targets.php?
https://pubmed.ncbi.nlm.nih.gov/40614724/
Theranostics for Cancer
Theranostics: A Powerful Diagnostic Tool and Cancer Treatment in One
Radiation therapy has been used to fight cancer for more than a century. But when cancer has spread to multiple areas of the body, traditional radiation can be limited—because it’s usually aimed at one location at a time and can affect healthy tissue nearby. Memorial Sloan Kettering (MSK) highlights a newer approach that is changing what’s possible for advanced and metastatic cancers: theranostics.
What Is Theranostics?
Theranostics combines the words therapy and diagnostics. It’s a treatment strategy that uses radioactive medicines to first find cancer cells and then treat them—using the same target. MSK’s theranostics motto captures the concept simply: “We see what we treat, and we treat what we see.”
How Theranostics Works
Theranostics typically happens in two steps:
- Find the cancer (“see it”)
Doctors infuse a patient with a radioactive drug containing a diagnostic isotope that binds to a specific target on cancer cells. Then a PET scan “lights up” where the drug has attached, revealing cancer sites that may be hard to see on standard imaging. - Treat the cancer (“treat it”)
If the target is confirmed, doctors give a treatment version of the same approach—this time loaded with a therapeutic isotope. The radiation works like a highly precise “smart bomb,” damaging cancer cell DNA while helping protect surrounding healthy tissue.
Why Theranostics Is Such a Big Deal
MSK notes several practical advantages of theranostics, especially for cancers that have spread:
- It can reveal the exact location of cancer cells that might be missed on conventional scans.
- It can help doctors evaluate whether treatment is working sooner.
- It can help clinical trials move more efficiently from imaging to treatment phases.
- It can treat multiple sites of disease throughout the body, not just one spot at a time.
- Even when it isn’t a cure, theranostics can be meaningful because it may offer effective control with good tolerability—supporting quality of life and daily living for many patients.
A Real Example: Theranostics for Metastatic Prostate Cancer (Pluvicto)
MSK shares the story of a patient with metastatic (stage 4) prostate cancer who joined a clinical trial using lutetium-177 PSMA-targeted therapy (Pluvicto). The treatment targets PSMA, a protein on prostate cancer cells, delivering radiation directly to those cells.
MSK also notes that the FDA approval expanded in 2025 to include more patients—specifically, people who had not yet received chemotherapy, increasing who may be eligible for this type of treatment.
Theranostics Beyond Prostate Cancer
Theranostics is also being developed for other cancers. MSK describes ongoing work to identify new targets, including efforts in neuroendocrine cancers and research into targets like DLL3. MSK researchers are also working toward theranostics applications in cancers such as breast cancer, brain tumors, melanoma, and pancreatic cancer.
What’s Next: A More Powerful Next Wave (Alpha Particles)
MSK highlights a “next wave” of theranostics using alpha-emitting radiopharmaceuticals—described as the most powerful form yet—and notes they opened a facility dedicated to producing these agents for clinical trials.
Questions to Ask Your Care Team
If you or a loved one is living with advanced cancer, you might consider asking:
- Do I have a target (biomarker) that could make me eligible for theranostics?
- Would a PET scan help identify targets or sites of disease more clearly?
- Are there clinical trials involving targeted radionuclide therapy that fit my diagnosis?
- What side effects are typical, and how might this compare to other options?
(This is informational only—your oncology team can help you understand what’s appropriate for your specific diagnosis.)
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re exploring treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Join our community to access trusted resources, education, and encouragement from others who understand the stage 4 journey.
Reference:
https://www.mskcc.org/news/theranostics-powerful-diagnostic-tool-and-cancer-treatment-in-one
Given 2 Years, Living 13 Strong
Living 13 Years Strong: Debbie’s Stage 4 Lung Cancer Journey of Hope and Persistence
Debbie was given two years after a stage 4 lung cancer diagnosis. Thirteen years later, she’s thriving—proof that hope and targeted therapy can change lives on a stage 4 lung cancer journey.
When Debbie was first diagnosed with stage 4 lung cancer, doctors told her she might only have one to two years left. Like many patients, she felt overwhelmed and afraid. But instead of giving up, she sought a second opinion and learned that her cancer carried the BRAF mutation. This discovery opened the door to targeted therapy through a clinical trial—something that gave her options beyond traditional chemotherapy and radiation.
Over the last 13 years, Debbie has faced many treatments, side effects, and setbacks, but also many breaks from therapy where she could live life more fully. She has outlived the predictions and now encourages other patients to stay hopeful, ask questions, and keep pushing for answers. Debbie’s story shows how advances in biomarker testing and targeted therapy can turn what once felt like an “end date” into years filled with milestones and new memories.
Her journey reminds us that no one is defined by statistics. For patients with advanced lung cancer, Debbie is living proof that hope, persistence, and medical progress can lead to more time and better quality of life. (Source: GO2 for Lung Cancer)
Read the complete article here >
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about stage 4 lung cancer and other aspects of living with late-stage cancer. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
Safer Cancer Drug Dosing Ahead
Safer Cancer Drug Dosing: ASCO and FDA Push for Optimal, Not Maximum, Doses
ASCO and the FDA promote safer cancer drug dosing by focusing on optimal cancer drug dosing—finding the optimal effective dose to reduce side effects and improve treatment tolerance. Learn more in this article about optimal cancer drug dosing.
Concerns are growing that cancer drugs may be given at higher doses than patients actually need, leading to unnecessary side effects and treatment interruptions. The American Society of Clinical Oncology (ASCO), working with the FDA, has issued new principles urging a shift from the old “maximum tolerated dose” approach toward finding the “optimal effective dose.” This matters for newer treatments like immunotherapies and targeted therapies, where higher doses don’t always improve results but often increase harmful side effects. Patient surveys show many people with advanced cancers struggle with severe treatment side effects, and oncologists frequently lower doses early on to help patients stay on therapy.
To fix this, ASCO recommends designing trials that test multiple dosage levels, tailoring studies to real-world patients, and improving how patient-reported side effects are tracked. These steps align with the FDA’s Project Optimus, which is pushing for better drug dosing in cancer research. For patients, this shift offers hope for treatment that works just as well—or better—while being easier to tolerate, helping people with advanced cancer focus on living fully instead of fighting side effects. (Source: Oncology News Central)
Read the complete article here >
Earlier detection and better-tolerated treatment often go hand in hand. If you’re interested in what’s on the horizon for catching cancer sooner, read Future of Cancer Screening: Multi-Cancer Early Detection Brings New Hope.
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like optimal cancer drug dosing, dosing strategy guidance from ASCO and the FDA, trial design, and initiatives like the FDA’s Project Optimus—along with other aspects of living with late-stage cancer. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
New Clues on How Cancer Spreads
New Clues on Cancer Metastasis: How “Shape-Shifting” Cells Spread and Survive
With cancer metastasis research, researchers uncover how metastatic cancer cells hide, adapt, and return—offering new hope for treatments that stop cancer spread and improve survival.
For decades, doctors have known that cancer’s deadliest threat comes not from the original tumor but from metastasis — when cancer spreads to other parts of the body. Up to 90% of cancer deaths are linked to this process. Now, researchers led by Dr. Joan Massagué at Memorial Sloan Kettering are uncovering important insights into how metastatic cells survive, hide, and return to grow new tumors years later. These “shape-shifting” cells act like stem cells, traveling back in time to earlier, more flexible states that allow them to adapt and resist treatment. They can also slip into dormancy, hiding from the immune system until the conditions are right to awaken and spread again.
Scientists are learning that metastatic cells use different strategies depending on the type of cancer and the organ they invade. They can even change their physical shape to avoid being destroyed by the immune system. These discoveries open new possibilities for treatment — from targeting the hidden “time traveler” state, to waking dormant cells so the immune system can attack them, to blocking proteins that allow cancer cells to evade detection. While challenges remain, Dr. Massagué emphasizes that metastasis is no longer an automatic death sentence. With advances in immunotherapy and targeted research, controlling — and in some cases curing — stage 4 cancer is becoming more possible than ever before. (Source: Memorial Sloan Kettering)
Read the complete article here >
As cancer screening evolves, researchers are also rethinking how cancer drugs are dosed to reduce side effects and help patients stay on therapy. Learn more about optimal cancer drug dosing and why “optimal” can matter more than “maximum.”
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like cancer metastasis research, including new findings on how metastasis works—mechanisms like dormancy and “shape-shifting” behavior—and how this research could inform future treatments. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
Future of Cancer Screening Shows Hope
Future of Cancer Screening: Multi-Cancer Early Detection Brings New Hope
Most cancers are still found late because only five types—colon, cervical, breast, lung, and prostate—have routine screening. A new direction called multi-cancer early detection (MCED) aims to spot cancers with a single test. Instead of hunting for tiny, hard-to-find tumor DNA fragments in the blood, researchers are building tiny “sensors” that circulate in the body and switch on when they meet enzymes made by early cancer cells. These sensors release a synthetic marker that shows up clearly in samples like urine, creating a much stronger, earlier signal than traditional tests in preclinical studies.
Why it matters: this approach could make screening simpler, more accurate, and more accessible—potentially even via low-cost strips for clinics with limited resources—and may help catch hard-to-find cancers (including lung cancer) sooner, when treatment works best. Logic-based sensor designs (think an “AND” gate requiring multiple cancer signals) may reduce false alarms, and early clinical use could include tracking treatment response or watching for recurrence. Safety testing is still ahead, but progress is rapid. If successful, MCED could shift many diagnoses from late-stage to early-stage—and offer hope and options for people living with or at risk for advanced disease. (Source: MIT Technology Review)
Read the complete article here >
As researchers work to detect cancer earlier through multi-cancer early detection (MCED), they’re also uncovering new insights into what happens when cancer spreads. Cancer metastasis research is revealing how “shape-shifting” cells can hide, adapt, and return—helping explain why some cancers come back years later and pointing to new treatment possibilities. Read New Clues on Cancer Metastasis: How “Shape-Shifting” Cells Spread and Survive to learn more.
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like cancer metastasis research and emerging cancer screening advances, including multi-cancer early detection (MCED), preclinical findings, AI screening, theranostics, and what’s next before clinical use. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
Hiking Through Stage 4 Cancer
Hiking Through Stage 4 Lung Cancer: Gerri’s Story of Strength and Hope
When Gerri was first told she had stage 4 lung cancer with an EGFR mutation, it felt like her world had flipped upside down. An active athlete and tennis pro, she never expected such a diagnosis. But instead of giving in to fear, she chose a path of strength and hope—continuing to hike, kayak, ski, and travel the world with her husband by her side. Just weeks after starting targeted therapy, she hiked 90 miles in Patagonia, a trip she once thought might never happen.
With the support of her family, her oncologist, and a caring social worker, Gerri has embraced both treatment and life’s adventures. She quilts for others, practices qigong, and continues to cross items off her bucket list—now on her second one. For her, lung cancer is only part of the story, not the definition of who she is. Her message to others is clear: keep moving, keep dreaming, and make plans for joy. “Control what you can,” she says, “and live fully with what you’ve been given.”
(Source: Gerri Allen, Lung Cancer Survivor Blog)
Read the complete article here >
Stay Connected with Stage 4 Hope
Hear more stories like Gerri’s—her journey hiking through stage 4 lung cancer—and other late-stage lung cancer stories from people living with cancer. Discover information on treatments, clinical trials, symptom management, and real stories from others on the same journey. Join our community to stay informed with the latest research updates, upcoming retreats, and educational events.
Living Fully: Joanne’s Cancer Journey
Living Fully with Non-Small Cell Lung Cancer: Joanne’s Story of Hope and Healing
When Joanne was diagnosed with non-small cell lung cancer in 2021, she couldn’t help but ask the same question many patients face: “Why me?” She had lived a healthy lifestyle, exercised, and avoided processed foods, yet found herself retracing her past for answers—secondhand smoke in childhood, brief years of social smoking, exposure to environmental toxins, stress, or perhaps random chance. Her pathology revealed an EGFR mutation, a genetic change often seen in people with little or no smoking history, which allowed her to begin targeted therapy after surgery and chemotherapy.
Over time, Joanne realized that focusing on blame only robs her of peace. Instead, she has chosen to center her life around gratitude, faith, and the love of her husband and community. With new advances in treatment, she believes lung cancer should no longer be viewed as an automatic death sentence or a punishment tied to smoking. Through sharing her story, Joanne hopes to break the stigma, reminding us that compassion and understanding—not judgment—are what every patient deserves. (Source: Joanne Gaget Blog)
Read the complete article here >
Stay Connected with Stage 4 Hope
Hear more stories like Joanne’s story of hope and healing after she was diagnosed with non-small cell lung cancer in 2021—and other late-stage lung cancer stories from people living with cancer. Discover information on treatments, clinical trials, symptom management, and real stories from others on the same journey. Join our community to stay informed with the latest research updates, upcoming retreats, and educational events.
Yoga, Meditation, and More Bring Relief
Yoga, Meditation, and Integrative Medicine Ease Cancer Treatment Side Effects
A new clinical trial shows that live, online classes in yoga, meditation, tai chi, and fitness can do more than just help patients feel calmer — they can actually reduce the side effects of cancer treatment. Patients who joined these virtual integrative medicine sessions during chemotherapy, radiation, immunotherapy, or targeted therapy reported less fatigue, anxiety, depression, and trouble sleeping. Remarkably, they also needed fewer hospital stays, and when they were admitted, their time in the hospital was much shorter.
This approach, offered through Memorial Sloan Kettering’s Integrative Medicine at Home program, costs $25 per month and is available to patients anywhere — not just those treated at MSK. Many patients find the classes give them both physical strength and emotional support by connecting with others going through cancer. Other services like acupuncture and music therapy can also play a role in making treatment more tolerable. Research continues to grow, with hopes of expanding access nationwide. For patients and caregivers, these integrative therapies provide a safe, evidence-based way to feel stronger and more supported throughout cancer treatment.
Read the complete article here >
You’re Not Alone—Connect with the Stage4Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like yoga and integrative therapy—and how friendship, community, and a positive mindset can make all the difference in your journey. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
Riding Through Cancer: Christy’s Story
Riding My Harley Through Cancer: Christy’s Stage 4 Lung Cancer Story
From riding her Harley to competing in strongman events, Christy’s journey shows how hope and targeted therapy can make life after diagnosis possible.
When Christy Erickson was diagnosed with stage IV lung cancer at just 41, she feared she wouldn’t see her children grow up. After months of unanswered questions and second opinions, genetic testing showed her tumor had an EGFR mutation. That result opened the door to a targeted therapy called osimertinib. The treatment gave her more time with her family and the chance to live fully, not just survive.
A Turning Point: Genetic Testing and Targeted Therapy
Genetic testing revealed that Christy Erickson’s lung cancer carried an EGFR mutation, making her eligible for osimertinib—a targeted therapy supported by years of clinical research. Although she wasn’t enrolled in the pivotal trial, she directly benefited from the breakthroughs that helped make the treatment widely available. Osimertinib (brand name Tagrisso) is an oral targeted therapy (an EGFR inhibitor) used for certain types of non-small cell lung cancer (NSCLC) with EGFR mutations (such as exon 19 deletions or L858R). It works by blocking overactive epidermal growth factor receptors (EGFR), which can help slow or stop cancer cell growth; common side effects may include diarrhea, skin changes, and low blood counts.
(Source: Winship Cancer Institute of Emory University)
Read the complete article here >
Stay Connected with Stage 4 Hope
Hear more stories like Christy’s—riding her Harley after being diagnosed with stage IV lung cancer at just 41, daring to dream and continuing to live on her terms—and other late-stage lung cancer stories from people living with cancer. Discover information on treatments, clinical trials, symptom management, and real stories from others on the same journey. Join our community to stay informed with the latest research updates, upcoming retreats, and educational events.
References:
1. https://www.cancerresearchuk.org/about-cancer/treatment/drugs/osimertinib
